Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310 yubykov@gmail.com
Список исп. литературыСкрыть список 1. Awouters FH, Lewi PJ. Forty years of antipsychotic Drug research – from haloperidol to paliperidone – with Dr. Paul Janssen. Arzneimittelforschung 2007; 57 (10): 625–32. 2. Bernardo M, Bioque M. Three-month paliperidone palmitate – a new treatment option for schizophrenia.Expert Rev Clin Pharmacol 2016; 9 (7): 899–904. 3. Brissos S, Veguilla MR, Taylor D et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4 (5): 198–219. 4. Brunton L, Knollman B, Hilal-Dandan R. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition. McGraw-Hill Education. 13th Ed. 2017. 5. Citrome L. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? CNS Spectr 2016; 21 (S1): 1. 6. Daghistani N, Rey JA. Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent. P T 2016; 41 (4): 222–7. 7. Dom R, Van Lommel R, Baro F. A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent. Acta Psychiatr Scand 1971; 47 (4): 399–410. 8. D'Souza S, Faraj J, DeLuca P. Microsphere delivery of Risperidone as an alternative to combination therapy. Eur J Pharm Biopharm 2013; 85 (3 Pt. A): 631–9. 9. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9 (Suppl. 5): 17–20. 10. González-Rodríguez A, Catalán R, Penadés R et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review. Patient Prefer Adherence 2015; 9: 695–706. 11. Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry 2005; 17 (3): 137–40. 12. Hedayati A, Yazdi SG, Dehghankelishadi P et al. Preparation, optimization and physicochemical characterization of Aripiprazole loaded nano-porous in situ forming implant. Pharm Nanotechnol 2017. 13. Herold R. Long-acting injection – four-times-a-year. Review of the 3-monthly paliperidone-palmitate injection. Article in Hungarian. Psychiatr Hung 2017; 32 (1): 96–107. 14. Huygens H, Vereecken JL, Tanghe A. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action. Psychiatr Neurol Neurochir 1973; 76 (4): 251–9. 15. Johnson DA. Review Historical perspective on antipsychotic long- acting injections. Br J Psychiatry 2009; 52 (Suppl.): S7–12. 16. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013; 7: 1171–80. 17. Knudsen P. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 1985; 322 (Suppl.): 51–75. 18. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother 2006; 7: 1005–16. 19. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68. 20. Llorca PM, Abbar M, Courtet P et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013; 13: 340. 21. López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull 2009; 79 (2): 130–41. 22. Mahesh R et al. Antidepressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression. Indian J Pharmaceutic Educ Res 2011; 45 (1): 46–53. 23. Meltzer HY, Fatemi SH. Treatment of schizophrenia. The American psychiatric text book of psychopharmacology. American Psychiatric Press, Washington 1998; p. 127–35. 24. Moncrieff J. The Bitterest Pills: The Troubling Story of Antipsychotic Drugs. Palgrave Macmillan 2013. 25. Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat 2016; 12: 917–29. 26. Navitha A, Jogala S, Krishnamohan C et al. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. J Adv Pharm Technol Res 2014; 5 (2): 84–9. 27. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012; 6: CD008296. 28. Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: Past and present. Indian J Psychiatry 2009; 51 (4): 324–6. 29. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995; 40 (3 Suppl. 1): S5–11. 30. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984; 103: 197–204. 31. Rocca P, Sandei L, Bava I, Frieri T. Risperidone long-acting injection in the treatment of first episode schizophrenia. Curr Psychopharmacol 2013; 2: 29–36. 32. Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975; 43: 103–13. 33. Stahl SM, Muntner N. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4th Ed. 2013. 34. Wang L, Wang A, Zhao X et al. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm 2012; 427 (2): 284–92. 35. Yerragunta B, Jogala S, Chinnala KM et al. Development of a novel 3-month drug releasing risperidone microspheres. J Pharm Bioallied Sci 2015; 7 (1): 37–44. 36. Машковский М.Д. Лекарственные средства. Изд. 14-е, перераб., испр. и доп. М.: Новая волна, 2002. / Mashkovskii M.D. Lekarstvennye sredstva. Izd. 14-e, pererab., ispr. i dop. M.: Novaia volna, 2002. [in Russian] 37. Оленева Е.В., Рывкин П.В., Ладыженский М.Я. Инъекционный палиперидона пальмитат трехмесячного действия (Тревикта) – новое слово в длительной терапии больных шизофрении. Совр. терапия психических расстройств. 2017; 1: 35–43. / Oleneva E.V., Ryvkin P.V., Ladyzhenskii M.Ia. In"ektsionnyi paliperidona pal'mitat trekhmesiachnogo deistviia (Trevikta) – novoe slovo v dlitel'noi terapii bol'nykh shizofrenii. Sovr. terapiia psikhicheskikh rasstroistv. 2017; 1: 35–43. [in Russian]